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DR. ABINANTI: Coming back to the disease of Icelandic sheep, maedi, this is
the only known viral infection which specifically results in lymphocytic infiltration of
the bronchi producing a chronic progressive obstructive respiratory disease. Similar
diseases of sheep in Europe and the United States are caused by serologically similar
viruses. Two relevant points concerning maedi are worth noting here. The first point
relates to a possible difficulty that may be encountered when looking for etiologic
agents in emphysema. Apparently, two strains of the virus exist. One strain, maedi,
produces only pulmonary disease; effects of the other strain, visna, while producing
lung lesions, are more strongly centered in the central nervous system. The second
point relates to host factors in disease causation. Infection with the maedi virus re-
sults in a prolonged leukocytosis and antibody formation, and in the majority of sheep
no other clinical signs develop. The Icelandic investigators have noted that those sheep
that proceed on to the clinical disease, maedi, are those producing the highest levels
of antibody. It is conceivable that individuals who are good antibody producers may
also be more prone to autoimmune disease, and that the clinical disease results from
such a secondary reaction.
The studies of Dr. Tyler and his associates have shown that impairing the function
of the bronchial artery in the horse results in the production of emphysema. Also in
the horse, infection with the equine arteritis virus, a virus of the herpes virus group,
results in widespread vasculitis. Even though the vasculitis is generalized, the physio-
logic state of the lung paremchyma may be more vulnerable, hence contributing to
the production of emphysema. It would seem profitable to search for a similar virus
pathology in a more easily managed host than the horse.
DR. MIDDLETON: I would like to ask Dr. Fox if he could name some of the
bacterial species which have neurominidase activity as do the mycoplasma and in-
fluenza microorganisms. And also, since there does seem to be some correlation be-
tween influenza and possibly mycoplasma in aggravating bronchitis and emphysema,
does he have any ideas about these relationships?
DR. FOX: I would refer you to Isacson's paper for the name of the organisms, al-
though Dr. Austrian perhaps could name some. The point that I was making is that
the relatively acute processes are not particularly relevant to chronic persistent respira-
tory disease. I don't have any specific examples, however.
DR. HILDRETH: The by-word of today's session seems to be "multifactorial,"
and all of us are impressed with the complexity of the problems being discussed. I
hesitate to add one more potential complexity, but in discussing hypersensitivity in
viral infections, one other potential area for consideration might be the effect viruses
have on different immune mechanisms. I refer to the influence of measles virus, and
certain other viruses on at least the cutaneous manifestations of delayed hypersensitivity
where such hypersensitivity is depressed by natural measles infections, and by im-
munization with live measles vaccine. Evidence obtained by in vitro studies of lym-
phocytes now suggests that the depression of the cutaneous manifestations of delayed
hypersensitivity may be reflected also at a cellular level.
If viruses have any effect in this system from the immunologic standpoint, I believe
we will have to consider that each virus may act in a different way. Conceivably
some may be enhancing an immune system and some may be depressing another type
of immune system.
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DR. KILBURN: It is difficult enough to talk about bronchitis or bronchiolitis or
centrilobular emphysema, but I think it is impossible to talk about the etiology of
chronic obstructive pulmonary disease. We have no evidence that this is a disease. So
why stand under the umbrella? Why not stand out in the rain? The cardiologists had
to begin to differentiate heart failure into types before they could find out anything
about it. We need to do the same with lung failure.
The question is: How do viruses get into cells? Presumably if we could answer
that question, we could begin to cope with the question of their importance. The corol-
lary of the question is: What pulmonary cells can they get into?
DR. FOX: I take it that last question was directed to me, but I would like to com-
ment on your comment first.
I certainly agree with you. I was in a sense constrained into being an advocate of
the viral etiology of the diseases, and I undertook the responsibility of trying to think
how they might play a role in this respect. I honestly do not believe that viruses will
turn out to be the etiologic agents. I do think they will prove to be important con-
tributory factors and so go along completely with the position that you just enunciated.
As far as viruses getting into cells are concerned, they have their various ways of
doing it. They have to attach to cell surfaces to begin with. This is in large part a
matter of rather specific compatibility between receptors on the surfaces of particular
cells and the viruses. They presumably are taken in by pinocytosis. From that point
on, they get uncoated and their nucleic acid is liberated. The nucleic acid then takes
over the direction of the cell in some respects-usually to the end object of making the
cell a factory for producing more virus particles.
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